Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „exposures“
Suchtreffer
Begriffe & Kennungen
Ibrance · 4.5 · Data from a DDI study in healthy male subjects indicated that palbociclib exposures were comparable when a sin
Eintrag öffnenIbrance · 4.5 · Data from a DDI study in healthy male subjects indicated that palbociclib exposures were comparable when a sin
Eintrag öffnenKaftrio · 4.5 · ELX and IVA are inhibitors of BCRP. Co-administration of IVA/TEZ/ELX, and IVA may increase exposures of medici
Eintrag öffnenKaftrio · 4.5 · ELX and IVA are inhibitors of BCRP. Co-administration of IVA/TEZ/ELX, and IVA may increase exposures of medici
Eintrag öffnenKriegsexposition
Eintrag öffnenLitfulo · 4.5 · Ritlecitinib did not produce clinically significant changes in the exposures of oral contraceptives (e.g., eth
Eintrag öffnenMedia Exposure
Eintrag öffnenMütterliche Exposition
Eintrag öffnenOntozry · 4.5 · Cenobamate may reduce exposures of products primarily metabolized by CYP3A4 and 2B6. Cenobamate may increase e
Eintrag öffnenRecarbrio · 4.5 · A clinical drug-drug interaction study demonstrated that imipenem and relebactam exposures do not increase by
Eintrag öffnenRinvoq · 4.5 · Upadacitinib has no relevant effects on plasma exposures of ethinyl estradiol, levonorgestrel, methotrexate, o
Eintrag öffnenRinvoq · 4.5 · Upadacitinib has no relevant effects on plasma exposures of ethinyl estradiol, levonorgestrel, methotrexate, o
Eintrag öffnenRinvoq · 4.5 · Upadacitinib is metabolised mainly by CYP3A4. Therefore, upadacitinib plasma exposures can be affected by medi
Eintrag öffnenRinvoq · 4.5 · Upadacitinib is metabolised mainly by CYP3A4. Therefore, upadacitinib plasma exposures can be affected by medi
Eintrag öffnenSoliris · 4.5 · Concomitant use of eculizumab with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduc
Eintrag öffnenSotyktu · 4.5 · Deucravacitinib does not meaningfully impact plasma exposures of rosuvastatin (BCRP and OATP substrate), metho
Eintrag öffnenStayveer · 4.5 · 8 After co-administration of bosentan for 9.5 days, the plasma exposures to lopinavir and ritonavir decreased
Eintrag öffnenStribild · 4.5 · Co-administration with Stribild may lead to decreased elvitegravir and/or cobicistat exposures and loss of the
Eintrag öffnenSymkevi · 4.5 · 7 exposure of ivacaftor and M1-IVA, while any potential changes in M6-IVA exposures are not expected to be cli
Eintrag öffnenTracleer · 4.5 · After co-administration of bosentan for 9.5 days, the plasma exposures to lopinavir and ritonavir decreased to
Eintrag öffnen